Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib

Friday, February 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a study published in Epigenomics that investigates the predictive significance of circulating histones in patients with hepatocellular carcinoma undergoing treatment with sorafenib. The research aims to establish a correlation between histone levels and treatment outcomes, potentially improving prognostic assessments in clinical settings.
Price reaction · baseline $21.6 (2024-02-15 close) · hit pre-market · 2 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-3.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Study highlights the predictive significance of circulating histones.
  • Research published in a reputable journal, Epigenomics.
  • Findings may enhance treatment strategies for hepatocellular carcinoma.

Full Press Release Details

Paper titled: Predictive significance of circulating histonesin hepatocellular carcinoma patients treated with sorafenib.
Salani, Latarani, Casadei-Gardini et al.
Published in Epigenomics 2022

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the study published in Epigenomics?

The study focuses on the predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.

Who are the authors of the study?

The study was authored by Salani, Latarani, Casadei-Gardini, and others.

Where was the study published?

The study was published in the journal Epigenomics in 2022.

What potential impact does the study have?

The findings may enhance prognostic assessments and treatment strategies for hepatocellular carcinoma.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare hepatocellular carcinoma sorafenib circulating histones epigenomics
Last updated: Feb 16, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk